Compare Funko Inc (FNKO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Novavax Inc — how do they compare? Funko Inc trades at $6.43 (market cap $363.97M), while Novavax Inc trades at $12.73 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 5× Funko Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Funko Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Novavax Inc for 59 Days on average.
| FNKO | NVAX | |
|---|---|---|
Market Cap | $363.97M | $1.82B |
Volume | 1,422,651 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $12.56 |
52-Week Low | $2.81 | $6.22 |
Typical Hold Time | 33 Days | 59 Days |
Enterprise Value | $584.62M | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.44, up 2.06% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised EBITDA guidance, though profitability remains challenged with negative net margins. Analyst sentiment is mixed with a 'Hold' consensus and $7.58 price target, representing 17.7% upside potential from current levels.
Investment outlook balances operational improvements against persistent profitability challenges. The stock offers potential upside from continued execution of the 'Make Culture POP!' strategy and margin expansion, but faces risks from consumer discretionary spending volatility and competitive pressures in the collectibles market.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
